Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 15/20 | 0.47 |
| ▸ | HTR2A | P28223 | 15/20 | 0.47 |
| ▸ | HTR7 | P34969 | 15/20 | 0.47 |
| ▸ | HTR6 | P50406 | 15/20 | 0.47 |
| ▸ | HTR1A | P08908 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | SYK | P43405 | 1/20 | 0.42 |
| ▸ | GBA1 | P04062 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oxalic Acid SCHEMBL4772211 | 0.96 | KDM4E (0.46) | DRD2HTR2AHTR7HTR6HTR1A | |
| SCHEMBL4771141 | 0.90 | GBA1 (0.43) | DRD2HTR2AHTR7HTR6HTR1A | |
| Hydrochloric Acid SCHEMBL4770876 | 0.89 | GBA1 (0.43) | DRD2HTR2AHTR7HTR6HTR1A | |
| SCHEMBL4772217 | 0.88 | HTR7 (0.42) | DRD2HTR2AHTR7HTR6HTR1A | |
| SCHEMBL4768837 | 0.88 | RXFP1 (0.45) | DRD2HTR2AHTR7HTR6HTR1A | |
| SCHEMBL4770341 | 0.87 | DRD2 (0.47) | DRD2HTR2AHTR7HTR6HTR1A | |
| Hydrochloric Acid SCHEMBL4766031 | 0.86 | DRD2 (0.46) | DRD2HTR2AHTR7HTR6HTR1A | |
| SCHEMBL4774328 | 0.85 | GBA1 (0.43) | DRD2HTR2AHTR7HTR6HTR1A | |
| SCHEMBL4775898 | 0.85 | MEN1 (0.43) | DRD2HTR2AHTR7HTR6MEN1 | |
| Oxalic Acid SCHEMBL4765127 | 0.84 | KDM4E (0.46) | DRD2HTR2AHTR7HTR6HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020013460-A1 | Condensed pyridine compound | EISAI CO., LTD | 2002-01-31 | — | — | US | claimed |
| EP-1020445-A1 | FUSED PYRIDINE DERIVATIVES | Eisai Co., Ltd. (JP) | 2000-07-19 | — | — | EP | claimed |
| EP-1020445-B1 | FUSED PYRIDINE DERIVATIVES | EISAI R&D MAN CO LTD (JP) | 2008-08-13 | — | — | EP | disclosed |
| EP-1020445-B1 | FUSED PYRIDINE DERIVATIVES | EISAI R&D MAN CO LTD (JP) | 2008-08-13 | — | — | EP | disclosed |
| US-6875761-B2 | Certain 1,3-disubstituted isoquinoline derivatives | EISAI CO., LTD. (JP) | 2005-04-05 | — | — | US | disclosed |
| US-20040204421-A1 | Certain 1,3-disubstituted isoquinoline derivatives | EISAI CO., LTD. | 2004-10-14 | — | — | US | disclosed |
| US-6340759-B1 | ANTISPASMODIC AGENTS | EISAI CO., LTD. (JP) | 2002-01-22 | — | — | US | disclosed |
| EP-1020445-A1 | FUSED PYRIDINE DERIVATIVES | Eisai Co., Ltd. (JP) | 2000-07-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020013460-A1 | Condensed pyridine compound | MUSK, HTR1A, PAX3 | DRD2 1877/4885HTR2A 63/4885HTR7 22/4885 |
| US-20040204421-A1 | Certain 1,3-disubstituted isoquinoline derivatives | MUSK, HTR1A, RYR1 | DRD2 237/4885HTR2A 40/4885HTR7 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.